Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

Also called NCT01730053

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 305 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01730053
Other papers using this trial's data
  • Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial Atherosclerosis, 2016-01 DOI, PubMed 26638010

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, France, Germany, Italy, Mexico, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01730053. Randomized; quadruple masking; primary purpose treatment. Start 2012-11-30 (actual); primary completion 2014-04-30 (actual). Results posted on 2015-10-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01730053
Content hash
15c937967ca9a60985800838206dcc6b3eb25e5eb24c831155eb9516b81dec8e